EP0785786A4 - Microbial synthesis of hiv protease inhibitors - Google Patents

Microbial synthesis of hiv protease inhibitors

Info

Publication number
EP0785786A4
EP0785786A4 EP95937602A EP95937602A EP0785786A4 EP 0785786 A4 EP0785786 A4 EP 0785786A4 EP 95937602 A EP95937602 A EP 95937602A EP 95937602 A EP95937602 A EP 95937602A EP 0785786 A4 EP0785786 A4 EP 0785786A4
Authority
EP
European Patent Office
Prior art keywords
protease inhibitors
hiv protease
microbial synthesis
microbial
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95937602A
Other languages
German (de)
French (fr)
Other versions
EP0785786A1 (en
Inventor
Ali Shafiee
Shieh-Shung T Chen
Byron H Arison
Randall R Miller
George M Garrity
Brian Heimbuch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0785786A1 publication Critical patent/EP0785786A1/en
Publication of EP0785786A4 publication Critical patent/EP0785786A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP95937602A 1994-10-25 1995-10-20 Microbial synthesis of hiv protease inhibitors Withdrawn EP0785786A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32863494A 1994-10-25 1994-10-25
US328634 1994-10-25
PCT/US1995/013628 WO1996012492A1 (en) 1994-10-25 1995-10-20 Microbial synthesis of hiv protease inhibitors

Publications (2)

Publication Number Publication Date
EP0785786A1 EP0785786A1 (en) 1997-07-30
EP0785786A4 true EP0785786A4 (en) 1998-01-28

Family

ID=23281761

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95937602A Withdrawn EP0785786A4 (en) 1994-10-25 1995-10-20 Microbial synthesis of hiv protease inhibitors

Country Status (4)

Country Link
EP (1) EP0785786A4 (en)
JP (1) JPH10507917A (en)
AU (1) AU702122B2 (en)
WO (1) WO1996012492A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612217A (en) * 1994-10-25 1997-03-18 Merck & Co., Inc. Streptomyces sp. MA 7074 (ATCC 55605) used for microbial synthesis of HIV protease inhibitors
EP0817789B1 (en) * 1996-01-26 2002-01-02 Roche Diagnostics Corporation Bis-maleimido cross-linking agents
US5763196A (en) * 1996-01-26 1998-06-09 Boehringer Mannheim Corporation Assays using cross-linked polypeptide fragments of β-galactosidase
US5976857A (en) * 1996-01-26 1999-11-02 Boehringer Mannheim Corporation Cross-linked polypeptide fragments of β-galactosidase
JP2004115510A (en) * 2002-09-05 2004-04-15 Toray Fine Chemicals Co Ltd Method for producing piperazine derivative
AU2003264365A1 (en) * 2002-09-05 2004-03-29 Toray Fine Chemicals Co, . Ltd. Process for producing oxycarbonyl-substituted piperazine derivative
CN101497608B (en) * 2009-03-05 2011-11-09 中国科学院广州生物医药与健康研究院 HIV protease inhibitor derivative, preparation thereof and use in antineoplastic medicament preparation
WO2024171717A1 (en) * 2023-02-17 2024-08-22 株式会社トクヤマ Manufacturing method for selexipag and purifying method therefor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012790A1 (en) * 1994-10-25 1996-05-02 Merck & Co., Inc. Microbial synthesis of hiv protease inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3160560A (en) * 1957-08-23 1964-12-08 Upjohn Co Streptolydigin and production thereof
JPS5774090A (en) * 1980-10-27 1982-05-10 Shionogi & Co Ltd Novel beta-galactosidase inhibitor, gt-2558, its derivative, and production
CA2081970C (en) * 1991-11-08 1997-07-08 Joseph P. Vacca Hiv protease inhibitors useful for the treatment of aids
CA2110827A1 (en) * 1992-12-14 1994-06-15 Maki Nishio Antiviral antibiotic bu-4724v and preparation thereof
SK279471B6 (en) * 1993-03-31 1998-11-04 Merck & Co. Compound composition, pharmaceutical agents containing thereof and their use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012790A1 (en) * 1994-10-25 1996-05-02 Merck & Co., Inc. Microbial synthesis of hiv protease inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9612492A1 *

Also Published As

Publication number Publication date
AU3966395A (en) 1996-05-15
EP0785786A1 (en) 1997-07-30
WO1996012492A1 (en) 1996-05-02
AU702122B2 (en) 1999-02-11
JPH10507917A (en) 1998-08-04

Similar Documents

Publication Publication Date Title
PL313871A1 (en) Inhibitors of hiv protease
PL314838A1 (en) Inhibitors of bp-iv-serine protease
PL322877A1 (en) Sulphonamidic inhibitors of aspartil hiv protease containing thf
AP9701054A0 (en) Inhibitors of cycteine protease
PL323710A1 (en) Reversible inhibitors of cysteinic protease
PL326508A1 (en) Protease inhibitors
PL307858A1 (en) Sulphonamidic inhibitors of aspartilic hiv protease
IL118101A0 (en) Inhibitors of farnesyltransferase
EP0744948A4 (en) Protease inhibitors
AU1271297A (en) Inhibitor of ceramidase
AU3868095A (en) Apolipoprotein-b synthesis inhibitors
PL328665A1 (en) Inhibitors of serinic protease
PL337725A1 (en) Inhibitors of proteases
PL319905A1 (en) Apolipoprotein b synthesis inhibitors
PL314486A1 (en) Precursors of hiv protease inhibitors
AU2251892A (en) Inhibitors of picornavirus proteases
HUP9802764A3 (en) Guanidino protease inhibitors
AU7523194A (en) Tick derived protease inhibitor
AUPM982594A0 (en) HIV protease inhibitors
EP0785786A4 (en) Microbial synthesis of hiv protease inhibitors
GB9515802D0 (en) Hiv protease inhibitors useful for the treatment of aids
AP2000001911A0 (en) Process for the synthesis of hiv protease inhibitors
EP0785989A4 (en) Microbial synthesis of hiv protease inhibitors
AU8159594A (en) Novel inhibitor
HU0900220D0 (en) Hiv protease inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970526

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

RHK1 Main classification (correction)

Ipc: C07D401/06

A4 Supplementary search report drawn up and despatched

Effective date: 19971215

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19981210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020501